Arcturus Therapeutics Holdings Receives Buy Recommendation from B. Riley Securities, Analysts Predict 453.90% Upside

B. Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with a Buy recommendation, projecting a 453.90% upside from its latest closing price. The average one-year price target is $35.39/share, with projected annual revenue of 531MM and non-GAAP EPS of -1.07. Institutional ownership has decreased by 46.91%, with Federated Hermes holding 11.62% of the company's shares.